ValueScreener

ValueScreener company report

aTyr Pharma, Inc. (ATYR)

NASDAQ / Healthcare / Biotechnology

Share price

0.18 USD Market dataClose of Oct 15, 2026

Market capitalisation

18.0M USD Market dataClose of Oct 15, 2026
Market data
Oct 15, 2026
Filed accounts
FY2025, filed Mar 5, 2026
Ratios computed
Oct 15, 2026
Filed years
12, FY2013 to FY2025
Four kinds of sourceSEC filingCompany statementMarket dataComputedWhat each means
SEC filingFiled with the SEC
Read from a statement the company filed with the SEC, with the form, fiscal year, filing date and accession beside it.
Company statementCompany statement
What the company says about itself in a filing: an 8-K item, the auditor, its own segment names.
Market dataMarket data
Prices, market value and what analysts publish, with the date they are as of.
ComputedComputed by ValueScreener
Worked out by us from the other three, with the inputs and the formula one press away. A score is a research output, not a rating or a recommendation.
Reading

1 of 10

Overview

What the business is, what it costs, and how it reads on four questions.

Market dataSEC filingComputed

Four questions, at a glance

Quality

Return on invested capital, after tax

-112.9% Computed

From the FY2025 filing

Read quality

Valuation

Price to book

0.25x Computed

FY2025 accounts, priced at the latest close

Read valuation

Cash generation

Free cash flow yield

n/m Computed

FY2025 accounts, priced at the latest close

Why n/m

Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

Read cash generation

Revenue and net income, as filed

FY2016 Net income: -57.9M USDFY2017 Net income: -48.2M USDFY2018 Net income: -34.5M USDFY2019 Revenue: 422.0K USDFY2019 Net income: -16.2M USDFY2020 Revenue: 10.5M USDFY2020 Net income: -16.2M USDFY2021 Revenue: 0.00 USDFY2021 Net income: -33.8M USDFY2022 Revenue: 10.4M USDFY2022 Net income: -45.3M USDFY2023 Revenue: 353.0K USDFY2023 Net income: -50.4M USDFY2024 Revenue: 235.0K USDFY2024 Net income: -64.0M USDFY2025 Revenue: 190.0K USDFY2025 Net income: -74.1M USD
Revenue Net income10 filed fiscal years, from the annual reports; the table in Filings names each document.
Named tests met
3 of 30 Which tests
The business, and the score behind its five axes

The reading, in brief

Is it good

Return on invested capital was -112.9% in FY2025, in the band labelled "Likely below the cost of capital" (below 8.0%), on lines anchored on Damodaran's cost-of-capital data, suggesting returns below the usual cost of the capital employed.

Today, against the Biotechnology industry (78 companies), -112.9% sits at the 31st percentile; the middle half of that group runs from -124.0% to -4.0%.

Is it safe

Debt to equity was 0.18 in FY2025, in the band labelled "Conservative" (below 0.50), on lines anchored on Graham's defensive-investor criteria, suggesting a balance sheet that relies little on borrowing.

Today, against the Biotechnology industry (252 companies), 0.18 sits at the 68th percentile; the middle half of that group runs from 0.01 to 0.29.

Year by year against peers
Whether aTyr Pharma, Inc.'s return on invested capital stayed above the median of the Biotechnology industry, year by year. (FY2023 to FY2025, 3 fiscal years of aTyr Pharma, Inc. with a comparable figure)
The direction
Which way aTyr Pharma, Inc.'s return on equity has moved, and how steadily. (FY2016 to FY2025, 10 filed years of aTyr Pharma, Inc.)
What could explain it
What in aTyr Pharma, Inc.'s filed statements could explain the movements. (4 readings drawn from the statement lines aTyr Pharma, Inc. filed)
What to check next
What to check next on aTyr Pharma, Inc., and where in its filings. (4 questions for aTyr Pharma, Inc.)
In one paragraph
One paragraph on aTyr Pharma, Inc.'s returns, cash, balance sheet and price. (8 of sixteen figures read for aTyr Pharma, Inc.)

These are ATYR’s filed figures. The research desk says what they mean, against peers and its own years, with what to check next.

Research ATYRPart of Serious. New accounts start with 30 days of Professional, free, no card.

2 of 10

What changed

The newest filing, what it moved, and when the next one is due.

SEC filingCompany statement

The newest accounts on file are the FY2025 annual report: 10-K, filed Mar 5, 2026, accession 0001339970-26-000008.

3 of 10

Quality

The returns the business earns on its capital, and the margins behind them.

SEC filingComputed

aTyr Pharma, Inc: returns on capital and margins, each with its source
FigureValue, source and document
Return on invested capital, after tax-112.9% ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Return on equity-109.8% ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Return on capital employed, pre-tax-99.7% ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Return on assets-79.7% ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Gross margin
Why n/a

Our archived statements for this filer carry no gross profit line, so there is nothing to compute a gross margin from and trace back to source. That may be because the filer presents no cost of revenue, or because we have not captured the concept. We do not guess which.

n/a ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Operating margin-40856.3% ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Net margin-39009.5% ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
ATYR -39009.5%
ATNM -37652.2%LITS -26647.9%LSTA -9756.5%TAOX -9609.2%INMB -91866.0%
-91866.0%-9609.2%
Net margin: ATYR against the 5 companies named under Valuation context, each as filed for its own latest year. Placement only: no average is drawn.

4 of 10

Financial strength

What it owes against what it owns, and whether it can meet what falls due.

SEC filingComputedCompany statement

aTyr Pharma, Inc: leverage, liquidity and distress, each with its source
FigureValue, source and document
Debt to equity0.18 ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Current ratio5.30 ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Quick ratio5.30 ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Interest coverage
Why n/a

No interest expense is filed for this year, so coverage is not computed.

n/a ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Altman Z-score-10.64 ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Net debt-66.7M ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Total assets 93.0MTotal liabilities 25.7MShareholders' equity 67.5MOwnsOwes, and equity
Total assets Total liabilities Shareholders’ equity
The balance sheet, line by line

Financial health

What aTyr Pharma, Inc owned and owed at the end of fiscal 2025, from the balance sheet it filed (10-K, filed Mar 5, 2026, 0001339970-26-000008).

aTyr Pharma, Inc: balance sheet position
Total assets93.0M FiledFY2025 10-K, filed Mar 5, 2026
Total liabilities25.7M FiledFY2025 10-K, filed Mar 5, 2026
Shareholders' equity67.5M FiledFY2025 10-K, filed Mar 5, 2026
Cash78.7M FiledFY2025 10-K, filed Mar 5, 2026
Total debt12.0M FiledFY2025 10-K, filed Mar 5, 2026
Net debt-66.7M
Current ratio5.30
Debt to equity0.18
  • Interest cover: FY2025: No interest expense is filed for this year, so coverage is not computed.

Read from the filed balance sheet for each year, with the income statement of the same year supplying operating profit where a ratio needs it. Nothing here is a view on whether this company is sound.

5 of 10

Valuation context

What the market charges for it, against its own record and companies like it.

Market dataSEC filingComputed

aTyr Pharma, Inc: what the market charges, each with its source
FigureValue, source and document
Price to earnings
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
P/E on trailing twelve months
Why n/a

Fewer than twenty trading days carry a meaningful trailing price to earnings ratio, so no range is stated.

n/a ComputedClose of Oct 15, 2026 · Trailing four quarters, each as known on the day; the quarterly filings are listed under Filings
Price to book0.25x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Price to sales89.95x ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Enterprise value to EBIT
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Enterprise value to EBITDA
Why n/m

EBITDA is zero or negative, so a multiple of it is not meaningful.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Price to earnings over growth
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Diluted earnings per share-0.80 USD FiledFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Graham number
Why n/m

Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.

n/m ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008

We publish no fair value or price target of our own. Value ATYR on your own assumptions in the DCF workbench, starting from the filed figures.

Its own record, and companies like it

Valuation

What the market charges for aTyr Pharma, Inc today, and the multiples it has carried. No value of ours: the figures are the filings’ and the market’s.

aTyr Pharma, Inc: valuation
Share price0.18 USD
Market capitalisation18.0M USD
Enterprise value to EBITDAn/m
Graham numbern/m
Diluted earnings per share, FY2025-0.80 USD

Price to earnings on trailing twelve months: Fewer than twenty trading days carry a meaningful trailing price to earnings ratio, so no range is stated.

Companies like aTyr Pharma, Inc

  1. Actinium Pharmaceuticals, Inc. (ATNM)Market cap 33.3M USD
  2. Lite Strategy, Inc. (LITS)Market cap 36.3M USD
  3. Lisata Therapeutics, Inc. (LSTA)Market cap 9.6M USD
  4. TAO Synergies Inc. (TAOX)Market cap 27.1M USD
  5. INmune Bio, Inc. (INMB)Market cap 45.8M USD

Same industry (Biotechnology) and size band (Nano, under 50M), nearest in market value, net margin and current ratio. Each of those counts equally, by how many of the companies considered sit between the two on it. Closest first: the order is likeness and nothing else.

6 of 10

Cash generation

Whether profit arrives as cash, and what is paid back to shareholders.

SEC filingComputed

aTyr Pharma, Inc: cash generation and what is paid out, each with its source
FigureValue, source and document
Free cash flow yield
Why n/m

Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.

n/m ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Free cash flow-62.1M USD ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Free cash flow margin-32664.7% ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Dividend yield
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedClose of Oct 15, 2026 · FY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Payout ratio
Why n/a

We do not hold this figure for this company, so there is nothing to show.

n/a ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
FY2016 Free cash flow: -53.5M USDFY2016 Net income: -57.9M USDFY2017 Free cash flow: -43.7M USDFY2017 Net income: -48.2M USDFY2018 Free cash flow: -31.7M USDFY2018 Net income: -34.5M USDFY2019 Free cash flow: -20.1M USDFY2019 Net income: -16.2M USDFY2020 Free cash flow: -15.5M USDFY2020 Net income: -16.2M USDFY2021 Free cash flow: -33.3M USDFY2021 Net income: -33.8M USDFY2022 Free cash flow: -43.5M USDFY2022 Net income: -45.3M USDFY2023 Free cash flow: -37.4M USDFY2023 Net income: -50.4M USDFY2024 Free cash flow: -69.2M USDFY2024 Net income: -64.0M USDFY2025 Free cash flow: -62.1M USDFY2025 Net income: -74.1M USD
Free cash flow Net incomeProfit that arrives as cash stands level with net income; a gap year after year is worth reading about.

7 of 10

Filings

Every figure, the year it is for and the document it was read from.

SEC filing

The filed figures

Computed from the accounts this company filed with the SEC and, in a ratio with a price in it, the last close, dated on this page. Every filed figure below carries the fiscal year and the filing date its accounts were read from, and every blank carries the reason it is blank. Nothing here is a view on this company.

aTyr Pharma, Inc.: the eight ratios, with the fiscal year and filing date behind each.
FigureValueYearAs of
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
0.25xFY2025Oct 15, 2026
n/aFY2025Oct 15, 2026
n/a Operating profit is zero or negative, so there is no profit for a buyer's price to be a multiple of.
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
-112.9%FY2025Mar 5, 2026
n/aFY2025Oct 15, 2026
n/a The filed cash flow statement reports no dividend paid at all. That is not the same as a filed zero, and we will not read it as one.
0.18FY2025Mar 5, 2026
5.30FY2025Mar 5, 2026
89.95xFY2025Oct 15, 2026
n/mFY2025Oct 15, 2026
n/m Not meaningful for this company, such as a P/E on negative earnings or a bank's EV/EBIT.
-10.64FY2025Oct 15, 2026
-2.93FY2025Mar 5, 2026
1/9FY2025Mar 5, 2026

The figures are computed from the accounts for fiscal 2025, the newest full year on file. 12 filed fiscal years on record, FY2013 to FY2025, from SEC EDGAR. Prices as of Oct 15, 2026. Ratios recomputed Oct 15, 2026. Two facts, because a recompute is not a fresh quote.

The year and the filing date name the statement each figure’s accounts are read from, and they stand even where the figure itself could not be computed: the line beneath a blank says what that statement did not carry. A figure’s name opens its formula and the filings behind it; a statement that names no SEC filing has no filing date, and reads n/a.

Ten years of filed figures, year by year

Ten years of filed figures

10 filed fiscal years, FY2016 to FY2025, read from the annual reports aTyr Pharma, Inc filed with the SEC. Each year names its filing. Amounts in USD, as filed.

aTyr Pharma, Inc: revenue, earnings, free cash flow and returns, by fiscal year, with the filing each year was read from
YearRevenueOperating incomeNet incomeEPS, dilutedFree cash flowOperating marginReturn on equityFiling
FY2025190.0K-77.6M-74.1M-0.80-62.1M-40856.3%-109.8%10-K, Mar 5, 20260001339970-26-000008
FY2024235.0K-67.9M-64.0M-0.86-69.2M-28899.6%-91.4%10-K, Mar 13, 20250000950170-25-038888
FY2023353.0K-54.9M-50.4M-0.94-37.4M-15557.8%-55.6%10-K, Mar 14, 20240000950170-24-031584
FY202210.4M-46.4M-45.3M-1.60-43.5M-446.8%-63.4%10-K, Mar 14, 20230000950170-23-007873
FY20210.00-34.0M-33.8M-1.77-33.3Mn/m-30.9%10-K, Mar 15, 20220001564590-22-010441
FY202010.5M-15.9M-16.2M-1.77-15.5M-152.2%-51.3%10-K, Mar 24, 20210001564590-21-014940
FY2019422.0K-23.0M-16.2M-7.03-20.1M-5445.0%-76.6%10-K, Mar 26, 20200001564590-20-013208
FY2018n/a-32.8M-34.5M-16.11-31.7Mn/a-102.6%10-K, Mar 26, 20190001564590-19-009381
FY2017n/a-47.1M-48.2M-26.13-43.7Mn/a-75.0%10-K, Mar 20, 20180001564590-18-006333
FY2016n/a-57.9M-57.9M-34.16-53.5Mn/a-92.1%10-K, Mar 16, 20170001564590-17-004631
  • Revenue, compound annual growth FY2019 to FY2025: -12.5%
  • Earnings: Earnings was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Earnings per share: Earnings per share was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.
  • Free cash flow: Free cash flow was not positive in both 2016 and 2025, so a compound rate across the window is not defined. Both figures are in the table.

Every figure in this section is a line of a filed annual statement or a ratio of two of them. Nothing here is estimated or smoothed. Earnings per share filed before a share split are put on today's share count, and say so. Nothing here is a verdict on the company.

8 of 10

Risks and guardrails

The accounting screens, the published tests, and the lines you can set to be told.

ComputedCompany statement

aTyr Pharma, Inc: accounting screens and published tests, each with its source
FigureValue, source and document
Beneish M-score-2.93 ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Piotroski F-score1/9 ComputedFY2025 10-K, filed Mar 5, 2026, 0001339970-26-000008
Named tests met3 of 30 Computed
Beta1.27 ComputedClose of Oct 15, 2026

The named tests

Of 30 tests value investors published: 3 met, 21 not met, 6 we could not complete. Counts, never a score: a single figure would have to decide that meeting one investor’s criteria and meeting another’s are worth the same.

Which tests, by name(all 30)
Meets
Two thirds of NCAV (Benjamin Graham); Book or below, low debt (Walter Schloss); Cheapest quarter on P/B (David Dreman)
Does not
Defensive investor (Benjamin Graham); Deep value; Large cap, low P/E; Earnings yield and ROIC (Joel Greenblatt); High F-score, low P/B (Joseph Piotroski); Three forensic scores; High returns and growth; EV/EBITDA and coverage; High yield, low payout; Dividends and buybacks; Low beta, profitable; ROIC at or above WACC; Near the 52-week low; Z-score and coverage (Edward Altman); High returns, low debt; Owner earnings yield; High return on tangibles; Low P/S, rising earnings (James O'Shaughnessy); Tangible book or below; Cash-flow yield and ROIC; Clean books, high ROIC
Not measured
Low PEG, low debt (Peter Lynch); Gross margin, turnover (Robert Novy-Marx); P/E times P/B (Benjamin Graham); Cash-covered dividend; Cheapest quarter on P/E (David Dreman); Low P/E, growth, yield (John Neff). A test with a figure we could not read is incomplete, never met and never failed.
Figures we could not read(13)
  • P/E Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • EV/EBIT: We do not hold this figure for this company, so there is nothing to show.
  • PEG Ratio: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Eps Growth 5Y: We do not hold this figure for this company, so there is nothing to show.
  • Gross Margin: Our archived statements for this filer carry no gross profit line, so there is nothing to compute a gross margin from and trace back to source. That may be because the filer presents no cost of revenue, or because we have not captured the concept. We do not guess which.
  • Asset Turnover: The stored figure is a zero that can stand for data we do not hold, so this test is not measured.
  • EV/EBITDA: EBITDA is zero or negative, so a multiple of it is not meaningful.
  • Interest Coverage: No interest expense is filed for this year, so coverage is not computed.
  • Dividend Yield: We do not hold this figure for this company, so there is nothing to show.
  • Payout Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Price To Graham: Earnings are zero or negative, so a price to earnings multiple is not meaningful. A negative P/E is not a cheap company and a large positive one from a near-zero denominator is not an expensive one.
  • Dividend Coverage Ratio: We do not hold this figure for this company, so there is nothing to show.
  • Dividend Streak: We do not hold this figure for this company, so there is nothing to show.

9 of 10

Declared positions

Whether anybody here owns this company.

Positions declared by the founder: no holding in any company shown here, as of October 3, 2026.

10 of 10

Next step

What to do with what you have read.

A thesis is your reason for owning it, in your words, with the figures that must stay true. Checking those figures every night against the newest filed accounts, and telling you once when one breaks, is what the subscription adds.

More on this company

What this cannot tell you

  • 13 figures could not be read on this company, among them P/E Ratio, EV/EBIT, PEG Ratio. Each blank in the table above names the rest, with its reason. 6 named tests come back incomplete because of them, which is neither met nor missed.

And the one that is true of all of it: This is what the numbers say today. It cannot tell you the day one of them stops being true. Nothing here can, because the reasons are not written down.

Running this once is arithmetic on public documents and you are welcome to it. Writing down why you own each company, in your own words and with the numbers that have to stay true for it to hold, and then having those numbers re-checked every night against the newest filed accounts, and against the latest close where a rule watches a price, is Professional, the plan a new account starts on for 30 days, one trial per person. It writes to you the day one breaks, and stays quiet when nothing does. The check runs every night at 23:30 UTC. A filing is picked up the night after it is published.

Monitor my portfolioHow this is computed

No card. 30 free days, and nothing is charged unless you choose a plan.

Analyze your own portfolio

ValueScreener · valuescreener.ai · Computed from accounts filed with the SEC by this company, read from EDGAR, and from dated closing prices. On this page a filed figure opens into its formula, its inputs and the statement, fiscal year and filing date it was read from, and a price into the day of its close. A figure that cannot show that trail says so.

A computation on accounts filed with the SEC, not a recommendation and not advice. Past filings do not indicate future results. Risk disclaimer.

Margin Notes

Once a week, what changed in the filings of US-listed companies, why it can matter to a thesis, and what deserves a closer review. Grounded in filings, not market noise.

Site map

Apps

  • Android app coming soon
  • iPhone app coming soon
ValueScreener

Discover companies, research each one to its filings, track what matters, and take your work into your own spreadsheet.

ValueScreener is a trading name of Oliva Real Estate Technologies LLC, a Delaware limited liability company. Legal notices: legal@valuescreener.ai. © 2026 Oliva Real Estate Technologies LLC. All rights reserved.

Risk disclaimer. This service is provided for research and education only. Nothing on it is investment advice, a recommendation, or an offer to buy or sell any security. Capital is at risk, and past performance does not indicate future results. Figures come from filed accounts and may be incomplete, delayed or later restated, so verify a number against the filing before you act on it.

With your permission, Google Analytics, Microsoft Clarity and HubSpot set cookies to measure how this site and the product are used, including recordings of sessions. Nothing is set unless you allow it. Privacy policy